{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:34:08Z","timestamp":1789122848960,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000875","name":"Pew Charitable Trusts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000875","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.drugalcdep.2025.112586","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T16:35:51Z","timestamp":1738168551000},"page":"112586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Real-world access to buprenorphine treatment in Philadelphia: A secret shopper study"],"prefix":"10.1016","volume":"268","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5450-6814","authenticated-orcid":false,"given":"Margaret","family":"Lowenstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Holliday","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2169-9562","authenticated-orcid":false,"given":"Shoshana V.","family":"Aronowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5246-709X","authenticated-orcid":false,"given":"Emily","family":"Seeburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6717-6735","authenticated-orcid":false,"given":"David","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2025.112586_bib1","unstructured":"Substance abuse and Mental Health Services Administration . TIP 63: Medications for Opioid Use Disorder For Healthcare and Addiction Professionals, Policymakers, Patients, and Families. 2021. 2021. https:\/\/store.samhsa.gov\/sites\/default\/files\/SAMHSA_Digital_Download\/PEP21-02-01-002.pdf.."},{"issue":"5","key":"10.1016\/j.drugalcdep.2025.112586_bib2","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1377\/hlthaff.2022.01513","article-title":"Buprenorphine treatment for opioid use disorder: comparison of insurance restrictions, 2017-21","volume":"42","author":"Andraka-Christou","year":"2023","journal-title":"Health Aff. (Proj. Hope)"},{"key":"10.1016\/j.drugalcdep.2025.112586_bib3","unstructured":"Aronowitz S.V.; Behrends C.N.; Lowenstein M.; Schackman B.; Weiner J. Lowering the Barriers to Medication Treatment for People with Opioid Use Disorder Evidence for a Low-Threshold Approach. 2022. https:\/\/ldi.upenn.edu\/wp-content\/uploads\/2022\/01\/Penn-LDI.CHERISH-Issue-Brief.January-2022.pdf."},{"key":"10.1016\/j.drugalcdep.2025.112586_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2021.107076","article-title":"Associations of housing stress with later substance use outcomes: a systematic review","volume":"123","author":"Austin","year":"2021","journal-title":"Addict. Behav."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112586_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M18-3457","article-title":"Access to office-based buprenorphine treatment in areas with high rates of opioid-related mortality: an audit study","volume":"171","author":"Beetham","year":"2019","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.drugalcdep.2025.112586_bib6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/add.13200","article-title":"Clinical risk factors for death after release from prison in Washington State: a nested case\u2013control study","volume":"111","author":"Binswanger","year":"2016","journal-title":"Addiction"},{"issue":"8","key":"10.1016\/j.drugalcdep.2025.112586_bib7","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1176\/appi.ajp.2016.16070792","article-title":"The role of behavioral interventions in buprenorphine maintenance treatment: a review","volume":"174","author":"Carroll","year":"2017","journal-title":"Am. J. Psychiatry"},{"issue":"16","key":"10.1016\/j.drugalcdep.2025.112586_bib8","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1056\/NEJMc2312906","article-title":"Buprenorphine dispensing after elimination of the waiver requirement","volume":"390","author":"Chua","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2025.112586_bib9","unstructured":"City of Philadelphia.Substance Use Prevention and Harm Reduction | Programs and initiatives. https:\/\/www.phila.gov\/programs\/substance-use-prevention-and-harm-reduction\/"},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112586_bib10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1521-0391.2013.12032.x","article-title":"Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users","volume":"22","author":"Cunningham","year":"2013","journal-title":"Am. J. Addict."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112586_bib11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12954-024-00964-5","article-title":"They make it too hard and too many hoops to jump: system and organizational barriers to drug treatment during epidemic rates of opioid overdose","volume":"21","author":"Dickson-Gomez","year":"2024","journal-title":"Harm Reduct. J."},{"issue":"16","key":"10.1016\/j.drugalcdep.2025.112586_bib12","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1001\/jama.2015.3474","article-title":"Emergency department-initiated buprenorphine\/naloxone treatment for opioid dependence: a randomized clinical trial","volume":"313","author":"D'Onofrio","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112586_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2012.07.005","article-title":"A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine","volume":"126","author":"Fiellin","year":"2013","journal-title":"Am. J. Med"},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112586_bib14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJMoa055255","article-title":"Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence","volume":"355","author":"Fiellin","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.drugalcdep.2025.112586_bib15","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1001\/jamapsychiatry.2021.0967","article-title":"Racial\/ethnic, social, and geographic trends in overdose-associated cardiac arrests observed by US emergency medical services during the COVID-19 pandemic","volume":"78","author":"Friedman","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugalcdep.2025.112586_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103715","article-title":"A mixed methods study of provider factors in buprenorphine treatment retention","volume":"105","author":"Gertner","year":"2022","journal-title":"Int. J. Drug Policy"},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112586_bib17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jamapsychiatry.2017.4614","article-title":"Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system","volume":"75","author":"Green","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.drugalcdep.2025.112586_bib18","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jsat.2013.10.004","article-title":"Leaving buprenorphine treatment: patients' reasons for cessation of care","volume":"46","author":"Gryczynski","year":"2014","journal-title":"J. Subst. Abus. Treat."},{"issue":"8","key":"10.1016\/j.drugalcdep.2025.112586_bib19","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1080\/10826084.2021.1908360","article-title":"\"The doctor says you cannot have [Buprenorphine]\" autonomy and use of prescribed or non-prescribed buprenorphine","volume":"56","author":"Hayes","year":"2021","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.drugalcdep.2025.112586_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109518","article-title":"Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states","volume":"237","author":"Hill","year":"2022","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112586_bib21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112586_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.34878","article-title":"Racial\/ethnic disparities in unintentional fatal and nonfatal emergency medical services-attended opioid overdoses during the COVID-19 pandemic in Philadelphia","volume":"4","author":"Khatri","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.drugalcdep.2025.112586_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019\"","volume":"110","author":"Krawczyk","year":"2022","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2025.112586_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.109915","article-title":"\"Come try it out. Get your foot in the door:\" exploring patient perspectives on low-barrier treatment for opioid use disorder","volume":"248","author":"Lowenstein","year":"2023","journal-title":"Drug Alcohol Depend."},{"issue":"12","key":"10.1016\/j.drugalcdep.2025.112586_bib25","article-title":"CareConnect: adapting a virtual urgent care model to provide buprenorphine transitional care","volume":"3","author":"Lowenstein","year":"2022","journal-title":"NEJM Catal."},{"issue":"3","key":"10.1016\/j.drugalcdep.2025.112586_bib26","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s11606-020-06257-4","article-title":"Barriers and facilitators to the use of medications for opioid use disorder: a rapid review","volume":"35","author":"Mackey","year":"2020","journal-title":"J. Gen. Intern. Med."},{"issue":"9","key":"10.1016\/j.drugalcdep.2025.112586_bib27","doi-asserted-by":"crossref","first-page":"628","DOI":"10.7326\/M18-1652","article-title":"The next stage of buprenorphine care for opioid use disorder","volume":"169","author":"Martin","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2025.112586_bib28","article-title":"Dialing for doctors: secret shopper study of Arizona methadone and buprenorphine providers, 2022","volume":"160","author":"Meyerson","year":"2024","journal-title":"J. Subst. Use Addict. Treat."},{"key":"10.1016\/j.drugalcdep.2025.112586_bib29","series-title":"Medications for Opioid Use Disorder Save Lives","first-page":"174","author":"National Academies of Sciences Engineering and Medicine","year":"2019"},{"issue":"6","key":"10.1016\/j.drugalcdep.2025.112586_bib30","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.18487","article-title":"Thematic analysis of state medicaid buprenorphine prior authorization requirements","volume":"6","author":"Nguemeni Tiako","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.drugalcdep.2025.112586_bib31","article-title":"Mayor Parker proposes cutting nearly $1 million in syringe exchange funding for Prevention Point","author":"Orso","year":"2024","journal-title":"Phila. Inq."},{"key":"10.1016\/j.drugalcdep.2025.112586_bib32","author":"Pew Charitable Trusts","year":"2021","journal-title":"Policies Should Promot. Access Buprenorphine Opioid Use Disord."},{"key":"10.1016\/j.drugalcdep.2025.112586_bib33","series-title":"Philadelphia 2022: The State of the City","author":"Pew Charitable Trusts","year":"2022"},{"issue":"6","key":"10.1016\/j.drugalcdep.2025.112586_bib34","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1056\/NEJMp1107779","article-title":"Taking the mystery out of \"mystery shopper\" studies","volume":"365","author":"Rhodes","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.drugalcdep.2025.112586_bib35","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2146\/ajhp170319","article-title":"Implementation and quality assessment of a pharmacy services call center for outpatient pharmacies and specialty pharmacy services in an academic health system","volume":"75","author":"Rim","year":"2018","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.drugalcdep.2025.112586_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108703","article-title":"Shorter outpatient wait-times for buprenorphine are associated with linkage to care post-hospital discharge","volume":"224","author":"Roy","year":"2021","journal-title":"Drug Alcohol Depend."},{"issue":"5","key":"10.1016\/j.drugalcdep.2025.112586_bib37","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/10826084.2023.2177972","article-title":"Scope of, motivations for, and outcomes associated with buprenorphine diversion in the United States: a scoping review","volume":"58","author":"Rubel","year":"2023","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.drugalcdep.2025.112586_bib38","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ (Clin. Res. Ed. )"},{"key":"10.1016\/j.drugalcdep.2025.112586_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108900","article-title":"Not in my treatment center: leadership's perception of barriers to MOUD adoption","volume":"144","author":"Stewart","year":"2023","journal-title":"J. Subst. Abus. Treat."},{"issue":"8","key":"10.1016\/j.drugalcdep.2025.112586_bib40","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1176\/appi.ps.20230522","article-title":"MOUD adoption among clients of organizations that provide MOUD or coordinate care with external providers","volume":"75","author":"Stewart","year":"2024","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.drugalcdep.2025.112586_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108176","article-title":"It's not just the money: the role of treatment ideology in publicly funded substance use disorder treatment","volume":"120","author":"Stewart","year":"2021","journal-title":"J. Subst. Abus. Treat."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112586_bib42","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13722-023-00365-2","article-title":"Substance use disorder bridge clinics: models, evidence, and future directions","volume":"18","author":"Taylor","year":"2023","journal-title":"Addict. Sci. Clin. Pract."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112586_bib43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.annemergmed.2019.04.020","article-title":"One-year mortality of patients after emergency department treatment for nonfatal opioid overdose","volume":"75","author":"Weiner","year":"2020","journal-title":"Ann. Emerg. Med"},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112586_bib44","doi-asserted-by":"crossref","first-page":"580","DOI":"10.2105\/AJPH.2019.305525","article-title":"Retention of patients with multiple vulnerabilities in a federally qualified health center buprenorphine program: Pennsylvania, 2017\u20132018","volume":"110","author":"Weinstein","year":"2020","journal-title":"Am. J. Public Health"},{"issue":"12","key":"10.1016\/j.drugalcdep.2025.112586_bib45","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial","volume":"68","author":"Weiss","year":"2011","journal-title":"Arch. Gen. Psychiatry"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871625000390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871625000390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T08:29:22Z","timestamp":1774427362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871625000390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":45,"alternative-id":["S0376871625000390"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112586","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world access to buprenorphine treatment in Philadelphia: A secret shopper study","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112586","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112586"}}